PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Vilanterol"

The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Relvar Ellipta ( Fluticason ...


Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting beta-2 agonist is more protective than a once-daily longacting beta-2 agonist alone against exacerbations of ...


Fluticasone furoate / Vilanterol ( FF/VI; Relvar Ellipta ) is an inhaled corticosteroid / long-acting beta2-agonist ( ICS / LABA ), recently approved as once-daily maintenance therapy for COPD. Rese ...


Results from two phase III studies were presented. They have shown that patients with chronic obstructive pulmonary disease ( COPD ) who received the anticholinergic, Incruse Ellipta ( Umeclidinium 62 ...


Combination long-acting bronchodilator therapy may be more effective than long-acting bronchodilator monotherapy in chronic obstructive pulmonary disease ( COPD ). The aim of a study was to compare ...


Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease ( COPD ). A study has c ...


Results from a third lung function study comparing the efficacy and safety of Umeclidinium and Vilanterol ( Anoro Ellipta; UMEC/VI ), a combination long-acting muscarinic antagonist ( LAMA ) / long-ac ...


Increased arterial stiffness as measured by aortic pulse wave velocity ( aPWV ) predicts cardiovascular events and mortality and is elevated in patients with COPD ( chronic obstructive pulmonary disea ...